Abstract Type 2 diabetes (T2DM) is a persistent metabolic disorder rising rapidly worldwide.
It is characterized by pancreatic insulin resistance and β-cell dysfunction. Hyperglycemia …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …

Epicardial adipose tissue has unique properties that distinguish it from other depots of
visceral fat. Rather than having distinct boundaries, the epicardium shares an unobstructed …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibition reduces heart failure
hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the …

Background The principal biological processes that characterize heart failure with a
preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a multifactorial disease
accounting for a large and increasing proportion of all clinical HF presentations. As a clinical …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Importance Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2
(SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events …